Artelo Biosciences, INC. (ARTL) — 8-K Filings

8-K Filings (24)

• 8-K Filing — Apr 7, 2026
• 8-K Filing — Nov 25, 2025
• Artelo Biosciences Files 8-K with Corporate Updates — Nov 14, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on November 14, 2025, reporting on events that occurred on November 10, 2025. The filing indicates amendments to its Artic
• Artelo Biosciences Files 8-K: Material Agreement & Financial Updates — Oct 31, 2025 Risk: medium
  Artelo Biosciences, Inc. entered into a Material Definitive Agreement on October 28, 2025. This agreement also created a Direct Financial Obligation for the reg
• Artelo Biosciences Announces Board and Compensation Changes — Oct 27, 2025 Risk: medium
  Artelo Biosciences, Inc. announced on October 26, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depart
• Artelo Biosciences Enters Material Definitive Agreement — Oct 17, 2025 Risk: medium
  Artelo Biosciences, Inc. entered into a material definitive agreement on October 15, 2025. The filing also includes financial statements and exhibits related to
• Artelo Biosciences Files 8-K — Oct 1, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on October 1, 2025, reporting on events that occurred on September 29, 2025. The filing indicates the entry into a materia
• Artelo Biosciences Files 8-K — Sep 15, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on September 15, 2025, reporting an event that occurred on September 11, 2025. The filing pertains to 'Other Events' and i
• Artelo Biosciences Files 8-K with Corporate Updates — Sep 10, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on September 9, 2025, reporting amendments to its Articles of Incorporation or Bylaws and submitting financial statements
• Artelo Biosciences Enters Material Definitive Agreement — Sep 5, 2025 Risk: medium
  On September 3, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company, formerly known as Reactive Medical Inc. and Knight Kno
• Artelo Biosciences Files 8-K — Sep 3, 2025 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on September 3, 2025, reporting other events. The company, incorporated in Nevada, is based in Solana Beach, CA, and opera
• Artelo Biosciences Files 8-K on Security Holder Vote — Aug 29, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on August 29, 2025, reporting on a matter submitted to a vote of its security holders on August 28, 2025. The filing does
• Artelo Biosciences Terminates Material Agreement — Aug 20, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on August 20, 2025, reporting the termination of a material definitive agreement. The filing also includes financial state
• Artelo Biosciences Files 8-K on Material Agreement & Equity Sales — Aug 7, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on August 7, 2025, reporting an entry into a material definitive agreement and unregistered sales of equity securities. Th
• Artelo Biosciences Files 8-K: Material Agreement, Equity Sales — Aug 4, 2025 Risk: medium
  On August 1, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Artelo Biosciences Files 8-K: Material Agreement & Exhibits — Jul 18, 2025 Risk: medium
  On July 18, 2025, Artelo Biosciences, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statem
• Artelo Biosciences 8-K: Convertible Notes Details — Jul 11, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on July 11, 2025, reporting on its financial condition and other events. The filing details convertible notes with provisi
• Artelo Biosciences Files 8-K: Material Agreement & Equity Sales — Jun 26, 2025 Risk: medium
  On June 24, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and
• Artelo Biosciences Files 8-K on Security Holder Rights — Jun 13, 2025 Risk: medium
  Artelo Biosciences, Inc. filed an 8-K on June 13, 2025, reporting material modifications to the rights of security holders and other events. The filing indicate
• Artelo Biosciences Faces Delisting Notice — May 23, 2025 Risk: high
  Artelo Biosciences, Inc. filed an 8-K on May 23, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, previously k
• Artelo Biosciences Files 8-K: Material Agreement & Equity Sales — May 1, 2025 Risk: medium
  On April 27, 2025, Artelo Biosciences, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Artelo Biosciences Faces Delisting Concerns — Apr 29, 2025 Risk: high
  Artelo Biosciences, Inc. filed an 8-K on April 29, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing
• Artelo Biosciences Files 8-K on Security Holder Votes — Dec 20, 2024 Risk: low
  Artelo Biosciences, Inc. filed an 8-K on December 20, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• Artelo Biosciences Appoints New CMO, Director Diamond Departs — Mar 4, 2024 Risk: medium
  Artelo Biosciences, Inc. announced on February 28, 2024, a change in its board of directors. Specifically, Dr. Robert L. Diamond resigned from his position as C

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX